GeneGo Center of Excellence Established at Yale’s Keck Lab
GeneGo said this week it has established the Keck Microarray Center at Yale University as a GeneGo Center of Excellence.
As a result, researchers at Keck will have access to MetaCore products, training, and advanced support. The Keck lab is expected to use Metacore to study basic and translation research, cancer biology, neuroscience research, and other clinical conditions, GeneGo said in a statement.
The Center of Excellence will provide an environment for the study of pathways and support for all of Yale’s researchers, and act as a training facility for GeneGo.
Financial terms were not disclosed.
Althea, Protein’eXpert Agree to Expand Development, Manufacturing Services
Althea Technologies and Protein’eXpert this week announced a letter of intent to create a complementary commercialization partnership.
The agreement will pair each company’s expertise to better serve growing biopharmaceutical development markets and extends the global commercial activities of each firm. Clients will be able to access Protein’eXpert’s protein engineering, process development, and optimization expertise and Althea’s good manufacturing practices knowledge.
The partnership will allow both companies to reach “larger markets, broaden services for new and challenging products, and to better match early- and late-stage client requirements for protein products,” Altheas said in a statement.
Financial terms of the deal were not revealed.
Althea provides technologies and services for pharmaceutical development and manufacturing. Protein’eXpert is a contract research organization with recombinant protein engineering and production services.
Boehringer Ingelheim Gains Access to MorphoSys Antibody Technology
Boehringer Ingelheim has exercised an option to use MorphoSys’s proprietary RapMAT antibody optimization technology.
The move by Boehringer, announced this week, extends an existing five-year agreement between the two firms. As part of the deal, MorphoSys’ HuCAL GOLD proprietary antibody library was earlier installed at Boehringer’s Vienna research site. As a result of the extended agreement, MorphoSys will receive annual user fees for the RapMAT technology.
No further financial terms were disclosed.
The existing agreement gives Boehringer the option to exclusively license multiple new therapeutic antibody programs. The collaboration currently encompasses four active therapeutic antibody programs “in various indications,” MorphoSys said in a statement. Two new programs were started recently and MorphoSys is optimizing HuCAL-derived antibodies for Boehringer.